STOCK TITAN

Shareholders of Perspective Therapeutics (NYSE: CATX) back board, auditor

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Perspective Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Of 114,017,755 common shares entitled to vote, 97,882,462 shares were represented, an 85.85% quorum. Stockholders elected six directors to serve until the 2027 annual meeting.

They also ratified WithumSmith+Brown, PC as independent registered public accounting firm for the fiscal year ending December 31, 2026. In an advisory vote on the frequency of say-on-pay, a one-year interval received the most support, and the company intends to hold annual advisory votes on executive compensation.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Shares outstanding entitled to vote 114,017,755 shares Common stock outstanding and entitled to vote at 2026 annual meeting
Shares represented at meeting 97,882,462 shares Shares represented in person or by proxy, 85.85% quorum
Quorum percentage 85.85% Percentage of entitled shares represented at 2026 annual meeting
Auditor ratification votes for 97,636,978 votes Votes for ratifying WithumSmith+Brown, PC for year ending December 31, 2026
Auditor ratification votes against 125,426 votes Votes against ratifying WithumSmith+Brown, PC
Say-on-pay 1-year frequency votes 76,479,166 votes Votes favoring annual advisory vote on executive compensation
Broker non-votes on director elections 20,599,237 votes Broker non-votes recorded for each director nominee
broker non-votes financial
"The votes were cast as follows Nominee | For | Withheld | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"ratified the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
non-binding advisory basis financial
"The stockholders of the Company voted, on a non-binding advisory basis, on how frequently future non-binding advisory votes"
A non-binding advisory basis is guidance or a recommendation offered for informational purposes that does not create legal obligations or guarantees; recipients can accept, modify, or ignore it without contractual consequences. Investors should treat it like a weather forecast for planning—useful for forming expectations and assessing risk, but not a firm promise—so they should verify assumptions, seek confirming information, and avoid relying on it as the sole basis for investment decisions.
emerging growth company regulatory
"Emerging growth company Item 5.07 Submission of Matters to a Vote of Security Holders."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Annual Meeting of Stockholders financial
"held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)."
0000728387false00007283872026-05-272026-05-27

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 27, 2026

 

 

Perspective Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-33407

41-1458152

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

c/o Perspective Therapeutics, Inc.

2401 Elliott Avenue

Suite 320

 

Seattle, Washington

 

98121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (206) 676-0900

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value

 

CATX

 

NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 27, 2026, Perspective Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 114,017,755 shares of common stock outstanding and entitled to vote at the Annual Meeting, 97,882,462 shares (or 85.85%) were represented, either in person or by proxy, constituting a quorum.

 

The following is a summary of the matters voted on at the Annual Meeting and the final voting results.

 

Proposal 1 – The Election Proposal. The stockholders of the Company elected Lori A. Woods, Heidi Henson, Maya Martinez-Davis, Frank Morich, M.D., Ph.D., Johan (Thijs) Spoor and Robert Froman Williamson, III to the Company’s Board of Directors (the “Board”) to hold office until the Company’s 2027 Annual Meeting of Stockholders and until his or her successor has been elected and qualified. The votes were cast as follows:

Nominee

For

Withheld

Broker Non-Votes

Lori A. Woods

69,622,536

7,660,689

20,599,237

Heidi Henson

74,298,922

2,984,303

20,599,237

Maya Martinez-Davis

77,085,447

197,778

20,599,237

Frank Morich, M.D., Ph.D.

62,317,819

14,965,406

20,599,237

Johan (Thijs) Spoor

77,090,696

192,529

20,599,237

Robert Froman Williamson, III

67,908,625

9,374,600

20,599,237

Proposal 2 – The Auditor Ratification Proposal. The stockholders of the Company ratified the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows:

For

Against

Abstain

Broker Non-Votes

97,636,978

125,426

120,058

-

Proposal 3 – Advisory Vote on Frequency of Advisory Stockholder Votes on Executive Compensation. The stockholders of the Company voted, on a non-binding advisory basis, on how frequently future non-binding advisory votes on the compensation of the Company’s named executive officers should be held. The votes were cast as follows:

1 Year

2 Years

3 Years

Abstain

Broker Non-Votes

76,479,166

274,495

364,497

165,067

20,599,237

 

In light of these voting results and other factors considered by the Board, the Company intends to hold a non-binding, advisory stockholder vote on the compensation of the Company’s named executive officers on an annual basis until the next required vote on the frequency of advisory votes to approve named executive officer compensation, or until the Board otherwise determines a different frequency for such non-binding votes.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

PERSPECTIVE THERAPEUTICS, INC.

 

 

 

 

Date:

May 27, 2026

By:

/s/ Chris Nenno

 

 

 

Chris Nenno
General Counsel and Corporate Secretary

 


FAQ

What was the shareholder turnout at Perspective Therapeutics (CATX) 2026 annual meeting?

Perspective Therapeutics reported strong participation, with 97,882,462 shares represented out of 114,017,755 eligible, resulting in an 85.85% quorum. This level of turnout enabled voting on directors, the auditor, and executive compensation frequency.

Which directors were elected at Perspective Therapeutics (CATX) 2026 annual meeting?

Stockholders elected Lori A. Woods, Heidi Henson, Maya Martinez-Davis, Frank Morich, M.D., Ph.D., Johan (Thijs) Spoor and Robert Froman Williamson, III. Each will serve on the board until the 2027 annual meeting and until a successor is elected and qualified.

Did Perspective Therapeutics (CATX) shareholders ratify the company’s auditor for 2026?

Yes. Shareholders ratified WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 97,636,978 votes for, 125,426 against, and 120,058 abstentions.

How did Perspective Therapeutics (CATX) shareholders vote on say-on-pay frequency?

In the advisory vote on how often to hold say-on-pay, 76,479,166 votes favored one year, 274,495 favored two years, 364,497 favored three years, and 165,067 abstained, with 20,599,237 broker non-votes recorded.

What frequency of executive compensation votes will Perspective Therapeutics (CATX) adopt?

In light of the advisory vote results and other factors, the board intends to hold a non-binding advisory stockholder vote on named executive officer compensation on an annual basis, until the next required vote on say-on-pay frequency or a different frequency is determined.

Filing Exhibits & Attachments

1 document